AR and prostate carcinoma: For example, a higher frequency of mutations in FOXA1, the gene encoding a pioneer factor that facilitates AR chromatin binding and transcriptional activation, was found in CRPC (12%) than in primary prostate cancer (4%) (Watson et al., 2013; Abeshouse et al., 2015).